MEG8: A Protein Targeted for Neurological Disorders (G79104)

Target Name: MEG8

NCBI ID: G79104

MEG8

MEG8: A Protein Targeted for Neurological Disorders

MEG8 (LINC00024) is a protein that is expressed in the brain and is known for its role in the development and progression of several neurological disorders, including Alzheimer's disease. The protein is also expressed in other tissues and has been shown to play a role in a variety of physiological processes, including cell signaling, inflammation, and stress response.

In recent years, researchers have been investigating the potential drug targets for MEG8 and have identified several potential targets that could be targeted with small molecules or antibodies. One of the most promising targets is the protein interacting with MEG8, which is known as PDZP2.

PDZP2 is a protein that is expressed in the brain and has been shown to interact with MEG8. The interaction between PDZP2 and MEG8 has been shown to play a role in the regulation of neural circuitry and in the development of neurological disorders. Researchers have identified several potential small molecules that can interact with PDZP2 and are currently in the process of testing these molecules for their ability to modulate the activity of MEG8.

Another promising drug target for MEG8 is the protein known as NF-kappa-B. NF-kappa-B is a protein that is involved in a variety of cellular processes, including inflammation, stress response, and cell signaling.MEG8 has been shown to interact with NF-kappa-B and the interaction has been shown to play a role in the regulation of neural circuitry and in the development of neurological disorders. Researchers have identified several potential small molecules that can interact with NF-kappa-B and are currently in the process of testing these molecules for their ability to modulate the activity of MEG8.

In addition to these drug targets, researchers have also been investigating the potential role ofMEG8 as a biomarker for the diagnosis and progression of neurological disorders.MEG8 has been shown to be expressed in the brains of individuals with a variety of neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. By using techniques such as mass spectrometry and affinity purification, researchers have been able to identify potential biomarkers for these disorders based on the expression of MEG8 in the brain. These biomarkers have the potential to be used for the diagnosis and monitoring of these disorders and could potentially be used in combination with other diagnostic tests to improve the accuracy of disease diagnosis.

Overall, MEG8 is a protein that has the potential to be a drug target for the treatment of a variety of neurological disorders. The interaction between MEG8 and other proteins, including PDZP2 and NF-kappa-B, suggests that there are several potential targets that could be modulated with small molecules or antibodies. Further research is needed to fully understand the role of MEG8 in neurological disorders and to develop effective treatments.

Protein Name: Maternally Expressed 8, Small Nucleolar RNA Host Gene

The "MEG8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MEG8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets